Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1984 May 1;159(5):1491–1501. doi: 10.1084/jem.159.5.1491

Selection of strongly immunogenic "tum-" variants from tumors at high frequency using 5-azacytidine

PMCID: PMC2187301  PMID: 6201588

Abstract

Highly immunogenic "tum-" (non-tumorigenic in normal syngeneic hosts) clonal variants can be selected from a variety of poorly immunogenic and highly tumorigenic mouse cell lines at very high frequencies (e.g., greater than 80%) after treatment in vitro with chemical mutagens such as ethyl methanesulfonate (EMS) or N-methyl-N'-nitro-N-nitrosoguanidine (MNNG). We herein demonstrate that the same result can be obtained with the poorly mutagenic cytidine analogue, 5-azacytidine, a strong DNA hypomethylating agent. 5-Azacytidine and EMS were equally and comparably effective, or ineffective, in inducing tum- variants from three different highly tumorigenic mouse cell lines. Like mutagen- induced tum- variants, those obtained after 5-azacytidine treatment generated usually strong cytolytic T lymphocyte (CTL) responses in vitro, and could grow in immunosuppressed (nude mouse) hosts. However, pretreatment of the tumor cell lines with 5-azacytidine did not cause significant increases in mutations at several independent drug- resistant gene loci, whereas EMS did. It is known that treatment of cells with 5-azacytidine can induce transcriptional activation of "silent" genes through a reduction of DNA 5-methylcytosine content, a process that can also be effected by mutagenic DNA alkylating agents such as EMS and MNNG. We therefore hypothesize that an "epigenetic" mechanism (DNA hypomethylation) leading to activation and expression of genes coding for potential tumor antigens is involved in the generation at high frequency of tum- variants after "mutagen" treatment. The implications of these findings to mechanisms of tumor progression and the generation of tumor heterogeneity are discussed.

Full Text

The Full Text of this article is available as a PDF (696.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boehm T. L., Drahovsky D. Alteration of enzymatic methylation of DNA cytosines by chemical carcinogens: a mechanism involved in the initiation of carcinogenesis. J Natl Cancer Inst. 1983 Sep;71(3):429–433. [PubMed] [Google Scholar]
  2. Boehm T. L., Grunberger D., Drahovsky D. Aberrant de novo methylation of DNA after treatment of murine cells with N-acetoxy-N-2-acetylaminofluorene. Cancer Res. 1983 Dec;43(12 Pt 1):6066–6071. [PubMed] [Google Scholar]
  3. Boon T., Kellermann O. Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line. Proc Natl Acad Sci U S A. 1977 Jan;74(1):272–275. doi: 10.1073/pnas.74.1.272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Boon T., Van Snick J., Van Pel A., Uyttenhove C., Marchand M. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis. J Exp Med. 1980 Nov 1;152(5):1184–1193. doi: 10.1084/jem.152.5.1184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Creusot F., Acs G., Christman J. K. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine. J Biol Chem. 1982 Feb 25;257(4):2041–2048. [PubMed] [Google Scholar]
  6. Doerfler W. DNA methylation and gene activity. Annu Rev Biochem. 1983;52:93–124. doi: 10.1146/annurev.bi.52.070183.000521. [DOI] [PubMed] [Google Scholar]
  7. Flatau E., Bogenmann E., Jones P. A. Variable 5-methylcytosine levels in human tumor cell lines and fresh pediatric tumor explants. Cancer Res. 1983 Oct;43(10):4901–4905. [PubMed] [Google Scholar]
  8. Frost P., Kerbel R. S., Bauer E., Tartamella-Biondo R., Cefalu W. Mutagen treatment as a means for selecting immunogenic variants from otherwise poorly immunogenic malignant murine tumors. Cancer Res. 1983 Jan;43(1):125–132. [PubMed] [Google Scholar]
  9. Frost P., Kerbel R. S. On a possible epigenetic mechanism(s) of tumor cell heterogeneity. The role of DNA methylation. Cancer Metastasis Rev. 1983;2(4):375–378. doi: 10.1007/BF00048568. [DOI] [PubMed] [Google Scholar]
  10. Frost P., Kerbel R. S., Tartamella-Biondo R. Generation of highly metastatic tumors in DBA/2 mice. Oncogenicity of a strain tumor cells. Invasion Metastasis. 1981;1(1):22–33. [PubMed] [Google Scholar]
  11. Gama-Sosa M. A., Slagel V. A., Trewyn R. W., Oxenhandler R., Kuo K. C., Gehrke C. W., Ehrlich M. The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res. 1983 Oct 11;11(19):6883–6894. doi: 10.1093/nar/11.19.6883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gasson J. C., Ryden T., Bourgeois S. Role of de novo DNA methylation in the glucocorticoid resistance of a T-lymphoid cell line. Nature. 1983 Apr 14;302(5909):621–623. doi: 10.1038/302621a0. [DOI] [PubMed] [Google Scholar]
  13. Hewitt H. B., Blake E. R., Walder A. S. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer. 1976 Mar;33(3):241–259. doi: 10.1038/bjc.1976.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kerbel R. S. Immunologic studies of membrane mutants of a highly metastatic murine tumor. Am J Pathol. 1979 Dec;97(3):609–622. [PMC free article] [PubMed] [Google Scholar]
  15. Kerbel R. S., Twiddy R. R., Robertson D. M. Induction of a tumor with greatly increased metastatic growth potential by injection of cells from a low-metastatic H-2 heterozygous tumor cell line into an H-2 incompatible parental strain. Int J Cancer. 1978 Nov 15;22(5):583–594. doi: 10.1002/ijc.2910220513. [DOI] [PubMed] [Google Scholar]
  16. Landolph J. R., Jones P. A. Mutagenicity of 5-azacytidine and related nucleosides in C3H/10T 1/2 clone 8 and V79 cells. Cancer Res. 1982 Mar;42(3):817–823. [PubMed] [Google Scholar]
  17. Riggs A. D., Jones P. A. 5-methylcytosine, gene regulation, and cancer. Adv Cancer Res. 1983;40:1–30. doi: 10.1016/s0065-230x(08)60678-8. [DOI] [PubMed] [Google Scholar]
  18. Uyttenhove C., Van Snick J., Boon T. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice. J Exp Med. 1980 Nov 1;152(5):1175–1183. doi: 10.1084/jem.152.5.1175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Van Pel A., Boon T. Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc Natl Acad Sci U S A. 1982 Aug;79(15):4718–4722. doi: 10.1073/pnas.79.15.4718. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Van Pel A., Georlette M., Boon T. Tumor cell variants obtained by mutagenesis of a Lewis lung carcinoma cell line: immune rejection by syngeneic mice. Proc Natl Acad Sci U S A. 1979 Oct;76(10):5282–5285. doi: 10.1073/pnas.76.10.5282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Van Pel A., Vessière F., Boon T. Protection against two spontaneous mouse leukemias conferred by immunogenic variants obtained by mutagenesis. J Exp Med. 1983 Jun 1;157(6):1992–2001. doi: 10.1084/jem.157.6.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Wigler M., Levy D., Perucho M. The somatic replication of DNA methylation. Cell. 1981 Apr;24(1):33–40. doi: 10.1016/0092-8674(81)90498-0. [DOI] [PubMed] [Google Scholar]
  23. Wilson V. L., Jones P. A. Inhibition of DNA methylation by chemical carcinogens in vitro. Cell. 1983 Jan;32(1):239–246. doi: 10.1016/0092-8674(83)90514-7. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES